PURE Bioscience, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
PURE Bioscience, Inc. (PURE) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised of 2.40 million shares for the 12-month period ending 2019-07-31, per its 10-K filed 2020-10-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised · last filed 2020-10-08
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2019 was 2.40M shares, a 54.97% decline from fiscal 2018.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2018 was 5.33M shares, a 1433.80% increase from fiscal 2017.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2017 was 347.45K shares.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2016 was -2.90M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 12 month as first filed |
|---|---|---|
| 2019-07-31 | 2.40M shares 10-K · filed 2020-10-08 | |
| 2018-07-31 | 5.33M shares 10-K · filed 2019-10-30 | |
| 2017-07-31 | 347.45K shares 10-K · filed 2018-10-25 | -347.45K shares 10-K · filed 2017-10-26 |
| 2016-07-31 | -2.90M shares 10-K · filed 2017-10-26 | |
| 2015-07-31 | -413.33K shares 10-K · filed 2016-10-27 |